<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03237026</url>
  </required_header>
  <id_info>
    <org_study_id>201705032RINA</org_study_id>
    <nct_id>NCT03237026</nct_id>
  </id_info>
  <brief_title>Predictive and Prognostic Markers for Treatment Outcomes in Prostate Cancer Patients</brief_title>
  <official_title>Decipher the Biology of Lethal Prostate Cancer-Using Urine Metabolomics and Proteomics Profiling to Search for Predictive and Prognostic Markers for Treatment Outcomes in Prostate Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Taiwan University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Taiwan University Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study aims to identify potential urine marker metabolites as predictive or prognostic&#xD;
      markers for treatment outcomes in patients with prostate cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single-center single-arm translational study where patients with prostate cancer&#xD;
      who are about to receive definitive treatments will be invited to participate the study.&#xD;
      After signing the approved informed consent, eligible and consenting subjects will donate&#xD;
      their fresh urine samples for subsequent untargeted metabolomics and proteomics study to&#xD;
      identify potential metabolite and protein markers that are able to predict responses&#xD;
      (including efficacy and side effects) to definitive treatments. All subjects who have&#xD;
      received varied treatment before the study can NOT be recruited.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 11, 2017</start_date>
  <completion_date type="Anticipated">July 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Biochemical recurrence or progression</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>toxicity profile, survival</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">360</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Cohort A</arm_group_label>
    <description>Ttaining chort will be recruited in the first 36 months of the study period to generate the first batch of urine metabolomic and proteomic profiles as predictive and prognostic markers.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B</arm_group_label>
    <description>Validation cohort will be recruited in the next 24 months of the study period .</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No intervention required</intervention_name>
    <description>No intervention required</description>
    <arm_group_label>Cohort A</arm_group_label>
    <arm_group_label>Cohort B</arm_group_label>
  </intervention>
  <biospec_descr>
    <textblock>
      fresh urine samples&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        A. Expected subject number to be enrolled: 360 men at NTUH.&#xD;
&#xD;
          1. Radical prostatectomy (OP, N=100): 50 subjects each for Cohort A and Cohort B,&#xD;
             respectively.&#xD;
&#xD;
          2. Radiotherapy (RT, N=140): 70 subjects each for Cohort A and Cohort B, respectively.&#xD;
&#xD;
          3. Androgen-deprivation therapy (ADT, N=60): 30 subjects each for Cohort A and Cohort B,&#xD;
             respectively&#xD;
&#xD;
          4. Systemic chemotherapy (Chemo, N=60): 30 subjects for Cohort A and Cohort B,&#xD;
             respectively&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subjects who have histopathologically confirmed prostate adenocarcinoma.&#xD;
&#xD;
          2. Subjects who age 30 years to 100 years&#xD;
&#xD;
          3. Subjects who agree to undergo the any of the following four treatments, including&#xD;
             radical prostatectomy, definitive prostate radiotherapy, systemic chemotherapy, and&#xD;
             androgen deprivation therapy for prostate cancer.&#xD;
&#xD;
          4. Subjects who understand and will comply with the entire study procedures, consent to&#xD;
             donate his spot urine (once for 50 ml) for urine metabolomics and proteomic profiling,&#xD;
             and agree with subsequent collection and analysis of his clinical information&#xD;
             including results of biopsy and the details of treatments and outcomes. (Note:&#xD;
             Subjects will be told that the urine metabolomics and proteomics results will not be&#xD;
             revealed to them.)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects who have other cancers that have not been curatively treated or are&#xD;
             disease-free for only 3 years or less. Subjects who have other genitourinary cancers&#xD;
             (urothelial, renal cell, etc) are NOT allowed no matter what the disease-free duration&#xD;
             is. However, subjects who have been curatively treated and are disease-free for 3&#xD;
             years or longer are allowed to be enrolled.&#xD;
&#xD;
          2. Subjects who have severe organ function impairment which may significantly alter&#xD;
             general cell metabolism or proteomics profiles determined by the investigators, such&#xD;
             as Cre &gt; 3.0, HbA1c &gt; 9.0%, symptomatic heart failure, or other symptomatic metabolic&#xD;
             diseases.&#xD;
&#xD;
          3. Subjects who have significant infection or inflammation within 8 weeks of the biopsy.&#xD;
&#xD;
          4. Subjects who are taking medicine(s) that may, deemed by the investigators,&#xD;
             substantially affect cell metabolism and proteomics profiles.&#xD;
&#xD;
          5. Subjects who have a life expectancy less than 12 months.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yeong-Shiau Pu, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Urology, National Taiwan University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chung-Hsin Chen, MD PhD</last_name>
    <phone>886-2-23123456</phone>
    <phone_ext>65242</phone_ext>
    <email>mufasachen@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yeong-Shiau Pu, MD PhD</last_name>
    <phone>886-2-23123456</phone>
    <phone_ext>65254</phone_ext>
    <email>pu5249@ntuh.gov.tw</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>National Taiwan University</name>
      <address>
        <city>Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yeong-Shiau Pu Pu, MD PhD</last_name>
      <phone>886-2-23123456</phone>
      <phone_ext>65254</phone_ext>
      <email>pu5249@ntuh.gov.tw</email>
    </contact>
    <contact_backup>
      <last_name>Chung-Hsin Chen, MD PhD</last_name>
      <phone>886-2-23123456</phone>
      <phone_ext>65242</phone_ext>
      <email>mufasachen@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>July 30, 2017</study_first_submitted>
  <study_first_submitted_qc>July 30, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 2, 2017</study_first_posted>
  <last_update_submitted>November 29, 2020</last_update_submitted>
  <last_update_submitted_qc>November 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>prostate cancer</keyword>
  <keyword>prostatectomy</keyword>
  <keyword>prostate radiotherapy</keyword>
  <keyword>chemotherapy</keyword>
  <keyword>immunotherapy</keyword>
  <keyword>biomarkers</keyword>
  <keyword>metabolomics</keyword>
  <keyword>proteomics</keyword>
  <keyword>urine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

